Last €76.49 EUR
Change Today +0.24 / 0.31%
Volume 1.6K
ALCAR On Other Exchanges
EN Paris
As of 10:40 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

carmat (ALCAR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/23/13 - €147.40
52 Week Low
07/1/14 - €69.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARMAT (ALCAR)

Related News

No related news articles were found.

carmat (ALCAR) Related Businessweek News

No Related Businessweek News Found

carmat (ALCAR) Details

Carmat Société Anonyme engages in designing and developing an implantable artificial heart. The company is developing orthotopic and biocompatible artificial heart, as well as its electrical power supply system and remote diagnosis system for patients suffering from chronic terminal heart failures. Carmat Société Anonyme was founded in 2008 and is based in Velizy Villacoublay, France.

39 Employees
Last Reported Date: 03/17/14
Founded in 2008

carmat (ALCAR) Top Compensated Officers

Chief Executive Officer, Director General and...
Total Annual Compensation: €385.0K
Compensation as of Fiscal Year 2012.

carmat (ALCAR) Key Developments

Carmat Société Anonyme, Annual General Meeting, Apr 02, 2014

Carmat Société Anonyme, Annual General Meeting, Apr 02, 2014.

Carmat Announces Continuation of the Clinical Trial on the First Bioprosthetic Artificial Heart

Carmat announced the continuation of the initial first-in-man clinical trial of its bioprosthetic artificial heart, in accordance with the applicable regulatory agreements. Following the announcement of the death, two and a half months after the implantation of the artificial heart, of the first patient, aged 76, CARMAT first and foremost wishes to pay tribute to the courage and the pioneering role of this patient and his family, and to thank the medical team's dedication and their contribution to this world first. The company would like to point out that this first implantation is part of an approved feasibility study involving four patients in an immediate life-threatening situation. Given these specific conditions, the clinical monitoring of a patient for 30 days or more after the artificial heart is implanted is considered to be encouraging. The first bioprosthetic heart, designed by Professor Alain Carpentier and developed in collaboration with CARMAT, beat for 74 days, that is some 7 million times, following its implantation on December 18, 2013 at the Georges Pompidou European Hospital in Paris. An analysis of the data is being carried out in accordance to the clinical trial's protocol. The company stresses that it is too soon to draw any conclusions from the data of a single patient, whatever the duration of the implantation.

Carmat Announces Earnings Results for the Financial Year Ending on December 31, 2013

Carmat announced earnings results for the financial year ending on December 31, 2013. for the year, total operating income was EUR 2,873,627 compared to EUR 17,989 a year ago. Operating loss was EUR 16,116,624 compared to EUR 22,385,513 a year ago. Financial loss was EUR 323,611 compared to profit of EUR 110,099 a year ago. Net loss was EUR 14,644,902 compared to EUR 17,189,691 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCAR:FP €76.49 EUR +0.24

ALCAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALCAR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALCAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 109.0x
Price/Book 21.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 102.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARMAT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at